Home › News › Quality / GMP

GSK's Velzatinib Receives Japan Orphan Drug Designation for GIST

GSK's Velzatinib Receives Japan Orphan Drug Designation for GIST

GSK has announced that its investigational drug velzatinib, a novel and highly selective KIT inhibitor, has received Orphan Drug Designation (ODD) from Japan’s Ministry of Health, Labour and Welfare for the treatment of Gastrointestinal Stromal Tumour (GIST). The designation is supported by findings from the ongoing Phase 1/1b StrateGIST 1 trial in patients with advanced GIST, which demonstrated anti-tumour activity and a tolerability profile considered promising by the company.

In addition to the Japanese designation, velzatinib has received Fast Track designation from the US Food and Drug Administration (FDA), as well as Orphan Drug Designation in the US and European Union (EU).

GSK is advancing the clinical development of velzatinib, with Phase 3 trials underway in patients with first- and second-line advanced or metastatic GIST. Enrolment in the second-line trial is progressing ahead of schedule, according to the company, with data expected in the second half of 2027. A separate Phase 2 study, StrateGIST J, is also underway in Japan to evaluate velzatinib in patients whose disease has progressed or who are intolerant to available treatment options.

Additional clinical and preclinical data on velzatinib are scheduled to be presented through seven abstracts at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2026, being held from November 18–21 in Seoul, South Korea. The presentations will include analyses of the drug in first- and second-line GIST by KIT mutation, research on its mutation coverage and studies of translational biomarkers. The findings are expected to provide further information on its development across different KIT mutations and lines of treatment.

Velzatinib is an investigational monotherapy designed to target clinically relevant primary and key secondary KIT mutations associated with GIST. These mutations are linked to tumour growth and treatment resistance, creating challenges for patients who develop resistance to existing therapies. GSK is developing the drug to address the range of KIT mutations involved in disease progression.

GIST is a rare cancer that most commonly develops in the stomach and small intestine. An estimated 80,000–120,000 people are diagnosed with the disease worldwide each year. Approximately 80 percent of GIST cases are associated with activating mutations in the KIT gene, particularly in exons 9 and 11. Around 90 percent of patients receiving first-line treatment develop additional secondary KIT mutations, commonly involving exons 13 and 17, which can lead to disease relapse and limit subsequent treatment options.

In Japan, the age-adjusted annual incidence of GIST is approximately four cases per 100,000 people, among the highest rates globally. Although treatment outcomes have improved over the past two decades, survival remains a challenge for patients with advanced or metastatic disease.

More news about: quality / gmp | Published by News Bureau | November - 20 - 2026

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members